WHO Grade 3 Glioma — Trials

WHO Grade 3 Glioma — Trials · CancerIndex

Clinical trials

Registered studies

258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 57
Recruiting: 32
Ph III recruiting: 2
Growth YoY: —
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 1–24 of 24 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05765812	A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma	recruiting	Phase 1 / Phase 2	116	Debiopharm International SAINDUSTRY	3	Sep 22, 2026	clinicaltrials
NCT07703436	Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease	not yet recruiting	Phase 2	40	Nuvation Bio Inc.INDUSTRY